Bio-Rad Laboratories, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bio-Rad Laboratories, Inc. on May 18, 2022. The report discloses an update regarding the Company's share repurchase program under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing focuses exclusively on capital allocation activities related to share repurchases. It does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
- Quarter-to-Date Repurchases (as of May 17, 2022): $125.0 million
- Shares Acquired (Quarter-to-Date): 255,000 shares
- Average Purchase Price: $489.65 per share (inclusive of commissions)
- Total Repurchased Under Program (Cumulative): $351.9 million
- Remaining Authorization: $98.1 million
Material Changes
The filing reports the execution of $125.0 million in share repurchases during the current quarter. This activity reduces the remaining authorization under the program from the prior balance to $98.1 million. No other material changes to financial condition or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, earnings outlook, or discussion of risks and contingencies. Management commentary is limited to the mechanics of the Share Repurchase Program, noting that repurchases are discretionary, have no time limit, and may be suspended or discontinued at any time. Acquired shares are designated for general corporate purposes, including supporting employee stock plans, funding acquisitions, and minimizing dilution.
Investor Verification Checklist
- Verify the remaining $98.1 million authorization balance against the most recent 10-Q or 10-K filings.
- Confirm the total number of shares outstanding post-repurchase to assess dilution impact.
- Review subsequent filings for any suspension or discontinuation of the repurchase program.
- Note that this 8-K does not provide operational or financial performance data for the quarter.